Drugs / ABBV-142
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06774313 | Jan 2025 → Apr 2026 | — | AbbVie | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07230288 | Jan 2026 → Sep 2029 expected | idiopathic pulmonary fibrosis | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-142 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06774313 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT06774313 ↗ |